Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Nikolay Pandev/E+ via Getty Images A couple of household names anchored the earnings releases on Wednesday morning. Home products retailer Bed Bath & Beyond (BBBY) and packaged foods maker General Mills (GIS) announced their quarterly results. AMMO, Inc. (POWW) also issued its financial f...
UNIONDALE, N.Y., June 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today anno...
Angion Biomedica (ANGN): Q1 GAAP EPS of -$1.56.Revenue of $0.37M (-57.5% Y/Y) misses by $1.52M.Press Release For further details see: Angion Biomedica misses on revenue
UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provid...
Angion Biomedica (ANGN) and Vifor Pharma have completed enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI).This indication is part of the ANG-3777 license agreement both parties signed in...
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated a...
Angion is a recent IPO. It has an ongoing phase 3 trial with near-term data readout. Cash balance is a little low. For further details see: Angion Biomedica: Interesting New IPO With Late Stage Asset Targeting A Novel Indication
Angion is pioneering a new approach to treating acute organ injuries with a pipeline of assets led by ANG-3777, a hepatocyte growth factor (HGF) mimetic. The company has a pivotal trial ongoing aimed at reducing the severity of Delayed Graft Function after kidney transplant. There...
Angion Biomedica (ANGN): Q4 GAAP EPS of -$1.90 misses by $0.60.Revenue of $0.46M (-34.3% Y/Y) misses by $1.44M.As of December 31, 2020, Angion had cash and cash equivalents totaling $34.6 million.Press Release For further details see: Angion Biomedica EPS misses by $0.60, misses on reve...
News, Short Squeeze, Breakout and More Instantly...
Angion Biomedica Corp. Company Name:
ANGN Stock Symbol:
NASDAQ Market:
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...
NEW YORK, NY / ACCESSWIRE / March 19, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ...